Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
作者： Michael S. Lee , Scott Kopetz
DOI: 10.1016/J.CLCC.2015.05.006
关键词:
摘要: The discovery of the key role epidermal growth factor receptor (EGFR) and its downstream signaling effectors in pathophysiology colorectal cancer (CRC) has ushered clinical use targeted therapies treatment metastatic CRC (mCRC). anti-EGFR monoclonal antibodies cetuximab panitumumab improve overall survival when combined with chemotherapy first-line Kirsten rat sarcoma viral oncogene homolog (KRAS) neuroblastoma RAS (NRAS) wild type mCRC also progression-free response rate refractory mCRC. There are ongoing efforts to discover mechanisms innate acquired resistance KRAS patients take therapeutic advantage this knowledge by using rational combinations therapies. In review we will discuss evidence for current several recent investigations refine mCRC, including more complete inhibition EGFR, HER2 inhibition, MET proto-oncogene, tyrosine kinase (MET) inhibition.
utsystem.edu参考文章(131)
Heike Allgayer, Douglas D. Boyd, Markus M. Heiss, Eddie K. Abdalla, Steven A. Curley, Gary E. Gallick, Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. ,vol. 94, pp. 344- 351 ,(2002) , 10.1002/CNCR.10221
X.-D. Yang, A. Jakobovits, Ping Wang, C. G. Davis, X.-C. Jia, J. R. F. Corvalan, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. ,vol. 59, pp. 1236- 1243 ,(1999)
William R Schelman, Daniel Mulkerin, Noelle K LoConte, Sam Lubner, Kyle D. Holen, KyungMann Kim, Michael Volk, Daniel Frank, Mary Beth Wims, J. Mitchell Winkler, Alcee Jumonville, Natalie Winterle, Katie Richter, Leah Dietrich, A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. Journal of gastrointestinal oncology. ,vol. 3, pp. 90- 96 ,(2012) , 10.3978/J.ISSN.2078-6891.2011.049
Carsten Bokemeyer, Claus-Henning Kohne, Fortunato Ciardiello, Heinz-Josef Lenz, Volker Heinemann, Ute Klinkhardt, Frank Beier, Klaus Duecker, Sabine Tejpar, Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. Journal of Clinical Oncology. ,vol. 32, pp. 3505- 3505 ,(2014) , 10.1200/JCO.2013.31.15_SUPPL.3537
Mari Iida, Toni M Brand, Megan M Starr, Chunrong Li, Evan J Huppert, Neha Luthar, Mikkel W Pedersen, Ivan D Horak, Michael Kragh, Deric L Wheeler, Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab Neoplasia. ,vol. 15, pp. 1196- 1206 ,(2013) , 10.1593/NEO.131584
S. Stintzing, D.P. Modest, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmueller, C. Kahl, G. Seipelt, F. Kullmann, W. Scheithauer, S. Held, C. Giessen, M. Moehler, A. Jagenburg, A. Jung, T. Kirchner, V. Heinemann, LBA11INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION Annals of Oncology. ,vol. 25, ,(2014) , 10.1093/ANNONC/MDU438.9
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
S. Q. Ashraf, A. M. Nicholls, J. L. Wilding, T. G. Ntouroupi, N. J. Mortensen, W. F. Bodmer, Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel Proceedings of the National Academy of Sciences of the United States of America. ,vol. 109, pp. 21046- 21051 ,(2012) , 10.1073/PNAS.1218750110
Gege Tan, Jeffrey D. Kearns, Nastaran Gerami-Moayed, Neeraj Kohli, Shannon L. Werner, Anne M. King, Callum M. Sloss, Raghida Bukhalid, Ulrik B. Nielsen, Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR. Molecular Cancer Therapeutics. ,vol. 10, ,(2011) , 10.1158/1535-7163.TARG-11-A210
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Świeboda-Sadlej, Niall C Tebbutt, Edith Mitchell, Irina Davidenko, Joe Stephenson, Elena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero, None, Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clinical Cancer Research. ,vol. 20, pp. 4240- 4250 ,(2014) , 10.1158/1078-0432.CCR-13-2752